Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biondvax Pharma ADR (NQ: BVXV )

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biondvax Pharma ADR

< Previous 1 2 3 4 5 Next >
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is ‘One to Watch’
Via Investor Brand Network
Teens Suffering from Concussions Could Benefit from Screen Time
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member
Via Investor Brand Network
Exposures COVID-19
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q3 2022 Financial Results, Corporate Updates
Via Investor Brand Network
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases
Via Investor Brand Network
Exposures COVID-19
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured in The Times of Israel Article
Via Investor Brand Network
Topics Economy
Exposures Supply Chain
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Congratulates Dirk Görlich on $1.4M World Laureates Association Prize in Life Sciences
Via Investor Brand Network
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at RAFT 14 Conference
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at LD Micro Main Event XV
Via Investor Brand Network
Aegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
NEW YORK, NY / ACCESSWIRE / January 3, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV). About... 
From Aegis Capital Corp.
Via AccessWire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.